Bayer's Nexavar gets priority review as thyroid cancer drug
August 27, 2013 at 02:44 AM EDT
FRANKFURT, June 2 (Reuters) - Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday.
